Revance Provides Corporate Update at Investor Day - Seite 2

A webcast replay will be available beginning September 19, 2023, at 12:00 p.m. PT / 3:00 p.m. ET. To access the replay, please register via the webcast link on the events page.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA. BOTOX is a registered trademark of Allergan, Inc.

Forward-Looking Statements

Any statements in this press release that are not statements of historical fact, including statements related to our adjusted gross margins; 2023 product revenue, operating expenses and research and development expense guidance and our guidance plans; our funding to cash flow breakeven; our capital requirements; the timing for reaching positive adjusted EBITDA; projected loss from the services segment; the plans for the OPUL business and the anticipated cash to be freed up from the exit of the OPUL payments business; our ability to successfully commercialize DAXXIFY, drive adoption, take market share and grow; our blockbuster potential; the competitive pricing of DAXXIFY; the potential benefits and performance of our products; the efficacy, duration and safety of DAXXIFY; our ability to set a new standard of care; potential benefits of our products to physicians and patients; development of a biosimilar to onabotulinumtoxinA for injection with Viatris; and our business and marketing strategy, timeline and other goals, and plans and prospects, including our commercialization plans; constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.